The POLVAS registry is designed for research purposes and includes retrospective and prospective databases. The retrospective part concentrates on epidemiology, clinical picture, as well as treatment safety and efficacy in the current routine care of vasculitis patients. The major aims of the prospective part include studies on pathogenesis, diagnostic and disease activity markers in serum, treatment efficacy and safety, long -term disease outcome including clinical and social consequences, and participation in clinical trials on novel therapeutic modalities in various vasculitis syndromes.
The members of the Consortium will also create vasculitis reference centers to offer the best possible diagnostic and therapeutic care for patients with vasculitis and to promote recent and future international vasculitis recommendations throughout the country.
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POLVAS will closely cooperate with other vasculitis registries created across Europe within the European Vasculitis Society (EUVAS) collaborative network. In association with the registry, a website for patients has also been created (www.zapalenianaczyn.pl) in order to provide a set of useful information about the various aspects of vasculitis syndromes.
Those who are interested in the cooperation with POLVAS are invited to visit the webpage at http://medicine.krakow.pl/POLVAS or contact the registry at POLVAS@cm -uj.krakow.pl.
To the Editor In 2014, we informed readers of this journal about the initiative to establish a Polish vasculitis registry. 1 According to the recommendations of the European Union Committee of Experts on Rare Diseases (EUCERD), such registries should be created to help elucidate the numerous gaps in our knowledge about medical and social impact of these diseases on the health care system. 2 It is now our pleasure to announce that the Scientific Consortium of the Polish Vasculitis Registry (Konsorcjum Naukowe Polskiego Rejestru Zapaleń Naczyń -POLVAS) has been created. 
